MedPath

Safety, PK and PD Study in Healthy Male Japanese Subjects

Phase 1
Completed
Conditions
Schizophrenia
Registration Number
NCT00447941
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Brief Summary

Study assessing pharmacokinetics, pharmacodynamics, safety, and tolerability of oral doses of SCA-136 in healthy male Japanese subjects

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
24
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
safety and tolerability
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath